<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9F97F39C-B9D6-4F6B-9E90-34E7DF66EBB5"><gtr:id>9F97F39C-B9D6-4F6B-9E90-34E7DF66EBB5</gtr:id><gtr:name>Viridian Pharma Limited</gtr:name><gtr:address><gtr:line1>A2 YEOMAN GATE , YEOMAN WAY</gtr:line1><gtr:city>WORTHING</gtr:city><gtr:postCode>BN13 3QZ</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F97F39C-B9D6-4F6B-9E90-34E7DF66EBB5" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>9F97F39C-B9D6-4F6B-9E90-34E7DF66EBB5</gtr:id><gtr:name>Viridian Pharma Limited</gtr:name><gtr:address><gtr:line1>A2 YEOMAN GATE , YEOMAN WAY</gtr:line1><gtr:city>WORTHING</gtr:city><gtr:postCode>BN13 3QZ</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>42452.0</gtr:offerGrant><gtr:projectCost>56602.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A</gtr:id><gtr:name>Aston University</gtr:name><gtr:address><gtr:line1>Aston Triangle</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:postCode>B4 7ET</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24249.0</gtr:offerGrant><gtr:projectCost>24249.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9825AE81-6EAC-4EF6-A025-E8314281F739"><gtr:id>9825AE81-6EAC-4EF6-A025-E8314281F739</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Martin</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131462"><gtr:id>6A3B3B71-4F12-4242-B2A6-E7EB73F53CB6</gtr:id><gtr:title>Development of a novel membrane coating technology for the formulation of orally disintegrating tablets to deliver flucloxacillin</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131462</gtr:grantReference><gtr:abstractText>Traditionally there has been a reluctance in the pharmaceutical industry to carry out clinical trials in children at the time of licensing. This has led to the scenario where many medicines are not specifically designed for use in children, which can result in poor effectiveness. To address this issue, the European Medicines Agency has recently issued a priority list for studies into non-patented medicinal products for children. This project hopes to exploit the objective of this list by undertaking research and development into medicines prioritised for need in children. The successful outcome of this project will be the development of age appropriate formulations for children, that will deliver medicines in an appropriate, efficacious and safe manner.</gtr:abstractText><gtr:fund><gtr:end>2014-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>66701</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131462</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>